Cancer and Alzheimer's disease: common starters, different roads

Israël, Maurice
January 2011
Cancer Therapy;2011, Vol. 8, p118
Academic Journal
The goal was to show that in addition to genetic factors, some common alterations of biochemical pathways are starters for both cancer and Alzheimer's disease. However, the pathways involved take different directions while the pathology develops. Understanding such mechanisms that lead to the observed lesions, may provide new possibilities for preventing or treating these plagues.


Related Articles

  • Journal of Alzheimer's Disease.  // Biomedical Market Newsletter;3/28/2012, Vol. 21, p1 

    The article focuses on a research published in the periodical "Journal of Alzheimer's Disease," which revealed that the FKBP52 protein may prevent the Tau protein from turning pathogenic and that it might help in developing new Alzheimer's drugs and for detecting the disease before the onset of...

  • Regulatory & Healthcare News.  // PharmacoEconomics & Outcomes News;6/12/2010, Issue 605, p15 

    The article reports on funding to be provided by New Zealand's drug subsidy agency Pharmac to the Donepezil-Rex brand of donepezil used for treating Alzheimer's disease and related types of dementia after it receives Medsafe approval.

  • Toward an Effective Treatment of Alzheimer's Disease. Blass, John P.; Weksler, Marc E. // Annals of Internal Medicine;Feb83, Vol. 98 Issue 2, p251 

    Editorial. Focuses on the treatment of Alzheimer's disease. Clinical manifestations of Alzheimer's disease; Technique in increasing acetylcholine concentration; Beneficial effects of oral physostigmine therapy.

  • Targeting Brain α7 Nicotinic Acetylcholine Receptors in Alzheimer's Disease: Rationale and Current Status. Vallés, Ana; Borroni, María; Barrantes, Francisco // CNS Drugs;Nov2014, Vol. 28 Issue 11, p975 

    Alzheimer's disease (AD) is the most common form of dementia among older persons. Pathognomonic hallmarks of the disease include the development of amyloid senile plaques and deposits of neurofibrillary tangles. These changes occur in the brain long before the clinical manifestations of AD...

  • Launching Now.  // Drug Store News;4/9/2001, Vol. 23 Issue 5, p11 

    Presents news briefs on new drug releases in the United States as of April 9, 2001. Anticipation of an international approval for Novatec's Glivec cancer drug; Approval of Reminyl Alzheimer's disease drug by the Food and Drug Administration; Launching of RemiFemin, an herbal supplement, by...

  • Chronic effects of anti-Alzheimer's drug, Galantamine hydrobromide on cholinergic system of mice brain. Kuna, Yellamma; Borra, Nirmala Kumari // Journal of Pharmacy Research;2013, Vol. 6/7 Issue 7, p714 

    Objectives: The present study emphasizes the prolonged effects of an anti-Alzheimer±'s drug, Galantamine hydrobromide (GHB) on morphometric, behavioural and cholinergic system in mice in the absence of the disease, AD. Methods: One month old male albino mice, Mus musculus (20 2 g) were...

  • Genentech and AC Immune Partner Again in Alzheimer's Disease. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 6, p91 

    Roche's Genentech has licensed global rights to develop and commercialise another Alzheimer's disease antibody programme from AC Immune, this time preclinical antibodies targeting the Tau protein. The deal is potentially worth more than CHF400 M (US$421 M) to AC Immune plus royalties on net...

  • Tau Gains Popularity as Alzheimer's Drug Target. Orelli, Brian // BioWorld Insight;7/2/2012, Vol. 20 Issue 27, p1 

    The article presents information on the tau protein which is a therapeutic target for the treatment of Alzheimer's disease. It informs that tau protein is more promising target for drug development than amyloid-beta for Alzheimer's disease treatment. The article informs about good correlation of...

  • New treatment strategies for Alzheimer's disease: is there a hope? Aprahamian, Ivan; Stella, Florindo; Forlenza, Orestes V. // Indian Journal of Medical Research;Oct2013, Vol. 138 Issue 4, p449 

    Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease, and corresponds to the most common cause of dementia worldwide. Although not fully understood, the pathophysiology of AD is largely represented by the neurotoxic events triggered by the beta-amyloid cascade and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics